TriLipix Approval Strengthens Abbott’s Cholesterol Franchise
Executive Summary
FDA approval of Abbott's next-generation fenofibrate TriLipix (fenofibric acid) reinforces the drug maker's position in the lucrative but maturing cholesterol market
You may also be interested in...
Abbott's Fibrate Franchise Will Likely Remain Limited To High-Risk Patients After ACCORD
Report from ACC: Experts advise reading the fine print of the study - which failed to show an overall outcome benefit - as sub-group analysis shows highest-risk patients might benefit.
AstraZeneca To Co-Promote Abbott’s TriLipix; NDA Is Filed For Crestor/TriLipix
AstraZeneca and Abbott announce co-promotion agreement for TriLipix ahead of an FDA decision on a jointly-developed investigational Crestor/TriLipix compound.
Solvay Analyzing “Various Options” For Its Pharma Unit
Belgian firm, which co-markets TriLipix and TriCor with Abbott, confirms it is in discussions with third-parties.